Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication
Sonia Jaramillo(Heidelberg University), Richard F. Schlenk(German Cancer Research Center), Lukas Baumann(Statistics Austria), Carsten Müller‐Tidow(Heidelberg University), Lucian Le Cornet(German Cancer Research Center), Markus Kratzmann(German Cancer Research Center), Meinhard Kieser(Heidelberg University), Christoph Schliemann(University Hospital Münster), Uwe Platzbecker(National Center for Tumor Diseases), Johannes Krisam(University Hospital Heidelberg), Martin Kaufmann(Robert Bosch Hospital), Sabine Käyser(German Cancer Research Center)
Cited by 0
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k